Core Points - ICU Medical, Inc. will release its first quarter 2025 earnings results on May 8, 2025, at approximately 4:00 p.m. ET [2] - A conference call to discuss the results will take place on the same day at 4:30 p.m. ET [2] - The conference call can be accessed via phone and will also be available through a webcast on the company's website [2] Company Overview - ICU Medical is a global leader in infusion systems, infusion consumables, and high-value critical care products [3] - The company focuses on providing quality, innovation, and value to clinical customers worldwide [3] - ICU Medical is headquartered in San Clemente, California [3]

ICU Medical (ICUI) announced at the 24th Annual Needham Virtual Healthcare Conference that it has developed a proactive strategy to mitigate the potential financial ramifications of the newly imposed tariffs announced by the Trump Administration. These tariffs, part of a broader trade policy shift, have already led to a notable decline in MedTech stocks and introduced uncertainty within the medical device industry. Despite these challenges, ICU Medical remains cautiously optimistic about its position, under ...

ICU Medical, Inc. (ICUI) , yesterday, announced the FDA’s 510(k) clearance for the Plum Solo precision IV pump, a single-channel complement to the dual-channel Plum Duo. The company also received the 510(k) clearance for updated versions of the Plum Duo precision IV pump and LifeShield infusion safety software, completing the initial launch of the ICU Medical IV Performance Platform.The Plum Solo expands the capabilities of the IV Performance Platform by offering a single-channel pump designed to work along ...

New devices address infusion delivery variability and expand the ICU Medical IV Performance Platform. SAN CLEMENTE, Calif., April 7, 2025 /PRNewswire/ -- ICU Medical Inc. (NASDAQ:ICUI), a worldwide leader in the development, manufacture and sale of innovative medical devices, has announced 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Plum Solo™ precision IV pump, a single-channel complement to the dual-channel Plum Duo™. ICU Medical also received 510(k) clearance for ...

SAN CLEMENTE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the 24th Annual Needham Virtual Healthcare Conference being held April 7-10, 2025. ICU Medical’s presentation will be on Monday, April 7, 2025 at 8:00 a.m. PT (11:00 a.m. ET). Company management will also be participating in one-on-one meetings on Monday, April 7, 2025. The presentation wi ...

Group 1 - ICU Medical will participate in a fireside chat at the KeyBanc Healthcare Forum on March 19, 2025, at 8:15 a.m. PT (11:15 a.m. ET) [1] - The fireside chat will be available for live webcast and replay on the company's website [2] - ICU Medical is a global leader in infusion systems and critical care products, focusing on quality, innovation, and value for clinical customers [3]

Financial Data and Key Metrics Changes - Revenue for Q4 was $622 million, representing a total company growth of 9% on a constant currency basis or 8% reported, aided by a temporary shortage in IV Solutions [9][10] - Adjusted EBITDA increased by 22% to $106 million compared to $86 million last year [27] - Adjusted diluted earnings per share for the quarter was $2.11, compared to $1.57 last year [25] Business Segment Data and Key Metrics Changes - Consumables business grew 6% both in constant currency and reported terms in Q4 [11] - IV Systems business grew 7% reported and 4% constant currency, marking the best absolute quarter in pumps [12] - Vital Care segment grew 16% on a constant currency and reported basis, primarily due to the national shortage in IV Solutions [13] Market Data and Key Metrics Changes - The broader demand and utilization environment in Q4 remained solid across almost every geography [10] - The capital environment is stable, with necessary investments being completed [10] Company Strategy and Development Direction - The company is preparing for a joint venture with Otsuka Pharmaceutical Factory, which is expected to enhance operational capabilities and customer service [14] - Focus on improving profitability through operational efficiencies and innovation in product offerings [44][50] - Plans to optimize the manufacturing network and logistics to achieve better gross margins [99] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving healthy revenue growth in all differentiated product lines [16] - The company aims to improve free cash flow by completing quality remediation and integration activities [40] - Management acknowledged the challenges posed by currency fluctuations and inflation but remains focused on operational improvements [50] Other Important Information - The company expects the IV Solutions JV transaction to close in Q2 2025, which will impact financial reporting [29][30] - Anticipated reduction in adjusted revenue of $350 million and adjusted EBITDA of $25 million post-JV transaction [31] Q&A Session Summary Question: What is driving the growth in Consumables? - Management indicated that growth was driven by a combination of new installations, global growth, and pricing [60] Question: What was the EBITDA margin excluding IV Solutions in 2024? - Management did not disclose specific figures but suggested that it would not be materially different from the reported total [62] Question: What is the demand environment for capital equipment? - Management described the environment as normal, with necessary capital investments being made [80] Question: Can you elaborate on the expected growth in Consumables? - Management expects all four product lines to contribute to growth, with confidence in legacy ICU lines [122] Question: What are the drivers for achieving the $500 million EBITDA goal? - Management highlighted sustained revenue growth, gross margin improvements, and currency stabilization as key drivers [128]

Financial Data and Key Metrics Changes - Revenue for Q4 was $622 million, representing a total company growth of 9% on a constant currency basis or 8% reported, aided by a temporary shortage in IV Solutions [9][10] - Adjusted EBITDA was $106 million, an increase of 22% compared to $86 million last year [27] - Adjusted diluted earnings per share (EPS) for the quarter was $2.11, compared to $1.57 last year [25] Business Segment Data and Key Metrics Changes - Consumables business grew 6% both in constant currency and reported terms in Q4 [11] - IV Systems business grew 7% reported and 4% constant currency, marking the best absolute quarter in pumps [12] - Vital Care segment grew 16% on a constant currency and reported basis, primarily due to the national shortage in IV Solutions [13] Market Data and Key Metrics Changes - The broader demand and utilization environment in Q4 remained solid across almost every geography [10] - The capital environment is stable, with necessary investments being completed [10] Company Strategy and Development Direction - The company is preparing for a joint venture with Otsuka Pharmaceutical Factory, which is expected to enhance operational capabilities and customer service [14] - Focus on improving profitability through operational efficiencies and innovation in product offerings [44][49] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving healthy revenue growth in all differentiated product lines and addressing under-earning issues [16][49] - The company aims to improve free cash flow and profitability by completing quality remediation and integration activities [40][53] Other Important Information - The company expects the IV Solutions JV transaction to close in the second quarter of 2025, impacting financial reporting [29][30] - Anticipated reduction in adjusted revenue of $350 million and adjusted EBITDA of $25 million post-JV transaction [31] Q&A Session Summary Question: What is driving the growth in Consumables? - Management indicated that growth was driven by a combination of new installs, global growth, and pricing [60] Question: What was the EBITDA margin excluding IV Solutions in 2024? - Management did not disclose specific figures but suggested using reported revenue and EBITDA for estimates [62] Question: What is the demand environment for capital equipment? - Management noted that capital outlays are being made, and transactions are moving forward [80] Question: Can you elaborate on the balance sheet and leverage after the JV? - Management stated a comfortable leverage ratio around 2 times is targeted, with expected deleveraging from the JV transaction [92] Question: What are the drivers for achieving the $500 million EBITDA goal? - Management highlighted sustained revenue growth, gross margin improvements, and currency stabilization as key drivers [128]

2023-2024 Revenue Performance - Total ICU adjusted revenue for 2023 was $2,213 million, while for 2024 it reached $2,335 million[6] - Consumables revenue grew by 7% year-over-year (YoY) in 2024, reaching $1,039 million compared to $969 million in 2023[6] - Infusion Systems revenue increased by 4% YoY in 2024, totaling $652 million versus $629 million in 2023[6] - Vital Care revenue saw a 5% YoY increase in 2024, amounting to $644 million compared to $615 million in 2023[6] 2025 Guidance (Excluding JV Transaction) - Adjusted EBITDA is projected to be between $395 million and $425 million[8] - Adjusted EPS is expected to be in the range of $655 to $725[8] - Revenue growth is anticipated to face a currency headwind of 10 to 15 percentage points[8] - Consumables and Infusion Systems are both expected to experience mid-single-digit growth[8] - Vital Care is projected to remain flat[8] - Gross Margin (GM) % is estimated to be between 37% and 38%[8] - OPEX % is expected to be approximately 24% of revenue[8] - Net interest expense is projected to be around $95 million[8] - The effective tax rate (ETR) is estimated at approximately 25%[8] - Diluted shares are expected to be 247 million[8] - Capital expenditure (CapEx) is projected to be between $90 million and $110 million[8] 2025 Guidance (Post JV Transaction) - Adjusted EBITDA is projected to be between $380 million and $405 million[8] - Adjusted EPS is expected to be in the range of $655 to $725[8] - Vital Care is expected to have flat ~ (37%) organic growth[8] - Gross Margin (GM) % is estimated to be between 39% and 40%[8] - OPEX % is expected to be approximately 26% of revenue[8] - Net interest expense is projected to be around $87 million[8] - Other Income/(Expense) is projected to be around $20 million[8] - The effective tax rate (ETR) is estimated at approximately 25%[8] - Diluted shares are expected to be 247 million[8] - Capital expenditure (CapEx) is projected to be between $75 million and $95 million[8]

Group 1 - ICU Medical reported quarterly earnings of $2.11 per share, exceeding the Zacks Consensus Estimate of $1.48 per share, and up from $1.57 per share a year ago, representing an earnings surprise of 42.57% [1] - The company achieved revenues of $621.62 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 3.95%, and an increase from $587.86 million year-over-year [2] - Over the last four quarters, ICU Medical has consistently surpassed consensus EPS and revenue estimates [2] Group 2 - The stock has underperformed the market, losing about 0.6% since the beginning of the year compared to the S&P 500's gain of 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is $1.14 on revenues of $569.1 million, and for the current fiscal year, it is $6.94 on revenues of $2.23 billion [7] - The Zacks Industry Rank indicates that the Medical - Products sector is in the bottom 49% of over 250 Zacks industries, which may impact stock performance [8] Group 3 - The estimate revisions trend for ICU Medical is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]